A study performed a multiomic profiling of baseline tumours in 77 patients with advanced cutaneous melanoma treated with anti-PD-1 with or without anti-CTLA-4 showing that overall response to any treatment was significantly associated with higher TMB (92). Here, PDCD1 is linked to neoplasm.